CTXR ($1.77) is undervalued by 15.84% relative to our estimate of its Fair Value price of $2.10 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
CTXR is good value based on its book value relative to its share price (3.9x), compared to the US market average (64.96x)
Valuation
CTXR is good value based on its book value relative to its share price (3.9x), compared to the US Biotechnology industry average (9.46x)
Valuation
1 of 5
CTXR News
Valuation
CTXR fair value
Fair Value of CTXR stock based on Discounted Cash Flow (DCF)
Price
$1.77
Fair Value
$2.10
Undervalued by
15.84%
CTXR ($1.77) is undervalued by 15.84% relative to our estimate of its Fair Value price of $2.10 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
CTXR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.85x
Industry
-5.79x
Market
15.24x
CTXR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.9x
Industry
9.46x
Market
64.96x
CTXR is good value based on its book value relative to its share price (3.9x), compared to the US market average (64.96x)
Valuation
CTXR is good value based on its book value relative to its share price (3.9x), compared to the US Biotechnology industry average (9.46x)
Valuation
CTXR's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.1M
Profit Margin
0%
CTXR's cash and short-term investments ($4.33M) cannot cover CTXR's cash burn for the next year ($21.38M), once increasing cash burn (110.51%) is accounted for
Financials
Assets to liabilities
Assets
$35.3M
Liabilities
$9.5M
Debt to equity
0.05
CTXR's short-term assets ($5.58M) exceed its short-term liabilities ($3.55M)
Financials
CTXR's long-term liabilities ($5.96M) exceed its short-term assets ($5.58M)
Financials
CTXR's debt relative to shareholder equity (0.38) has decreased or remained constant compared to 5 years ago (-1.22)
Financials
CTXR's debt to equity ratio (0.38) is considered acceptable
Financials
Cash flow
Operating
-$9.6M
Investing
$0.0
Financing
$500.0
CTXR's cash and short-term investments ($4.33M) cannot cover CTXR's cash burn ($21.38M) for 1 year
Financials
Citius Pharmaceuticals Stock FAQ
What is Citius Pharmaceuticals's quote symbol?
(NASDAQ: CTXR) Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol CTXR. Citius Pharmaceuticals stock quotes can also be displayed as NASDAQ: CTXR.
How much is Citius Pharmaceuticals's stock price per share?
(NASDAQ: CTXR) Citius Pharmaceuticals stock price per share is $1.77 today (as of Mar 4, 2021).
What is the 52 week high and low for Citius Pharmaceuticals (NASDAQ: CTXR)?
(NASDAQ: CTXR) Citius Pharmaceuticals's 52-week high was $2.90, and its 52-week low was $0.42. It is currently -38.97% from its 52-week high and 326.51% from its 52-week low.
What is Citius Pharmaceuticals's Market Cap?
(NASDAQ: CTXR) Citius Pharmaceuticals's market cap is $98.37M, as of Mar 5, 2021.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Citius Pharmaceuticals's market cap is calculated by multiplying CTXR's current stock price of $1.77 by CTXR's total outstanding shares of 55,576,996.
How much is Citius Pharmaceuticals stock worth today?
(NASDAQ: CTXR) Citius Pharmaceuticals currently has 55,576,996 outstanding shares. With Citius Pharmaceuticals stock trading at $1.77 per share, the total value of Citius Pharmaceuticals stock (market capitalization) is $98.37M.
Citius Pharmaceuticals stock was originally listed at a price of $6.10 in Jul 6, 2017. If you had invested in Citius Pharmaceuticals stock at $6.10, your return over the last 3 years would have been -70.98%, for an annualized return of -33.8%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.